A number of global ‘mega-trends’, such as dated technology and manufacturing inefficiencies, present major challenges for the drug industry, according to Dave Tudor
Chinese investors are looking abroad for technology that will provide short-term returns and long-term health benefits to its large patient population, according to Panacea Ventures partner.
The second phase of Changzhou Qianhong Bio-pharma manufacturing project sees a further ¥1 billion devoted to increasing tablet and injection production.
Cambrex is investing $1m at its High Point, NC-based site, marking the most recent in a series of investments which will see the addition of 1,300 square feet and 15 new employees.
According to the lentiviral vector manufacturer, which supplies vectors for Novartis’ Kymriah, the market is growing – and could be worth $800m by 2026.
